Perspectives

The Molecular, the Bad, and the Ugly: Preventing Bladder Cancer via mTOR Inhibition. David J. McConkey and Colin P. Dinney ........................................................................................................ 1001

Is It Time to Advance the Chemoprevention of Environmental Carcinogenesis with Microdosing Trials? Thomas W. Kensler and John D. Groopman ........................................................................................................ 1003

Research Articles

Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer. Catherine M. Seager, Anna M. Puzio-Kuter, Trushar Patel, Shalini Jain, Carlos Cordon-Cardo, James Mc Kiernan, and Cory Abate-Shen ........................................................................................................ 1008

Effects of Chlorophyll and Chlorophyllin on Low-Dose Aflatoxin B1 Pharmacokinetics in Human Volunteers. Carole Jubert, John Mata, Graham Bench, Roderick Dashwood, Cliff Perciera, William Tracewell, Kenneth Turteltaub, David Williams, and George Bailey ........................................................................................................ 1015

Gender Modifies the Effect of Ursodeoxycholic Acid in a Randomized Controlled Trial in Colorectal Adenoma Patients. Patricia A. Thompson, Betsy C. Wertheim, Denise J. Roe, Erin L. Ashbeck, Elizabeth T. Jacobs, Peter Lance, María Elena Martínez, and David S. Alberts ........................................................................................................ 1023

Dietary Tricin Suppresses Inflammation-Related Colon Carcinogenesis in Male Crj:CD-1 Mice. Takeru Oyama, Yumiko Yasui, Shigeyuki Sugie, Mamoru Koketsu, Kunitomo Watanabe, and Takuji Tanaka ........................................................................................................ 1031


Triterpenoids CDDO-Methyl Ester or CDDO-Ethyl Amide and Rexinoids LG100268 or NRX194204 for Prevention and Treatment of Lung Cancer in Mice. Karen Liby, Renee Risingsong, Darlene B. Royce, Charlotte R. Williams, Tian Ma, Mark M. Yore, and Michael B. Sporn ........................................................................................................ 1050

Preventive Effects of Bexarotene and Budesonide in a Genetically Engineered Mouse Model of Small Cell Lung Cancer. Yian Wang, Weidong Wen, Yijun Yi, Zhongqiu Zhang, Ronald A. Lubet, and Ming You ........................................................................................................ 1059


Distinct Effects of Calorie Restriction and Exercise on Mammary Gland Gene Expression in C57BL/6 Mice. Michela Padovani, Jackie A. Lavigne, Gadiessiti V.R. Chandramouli, Susan N. Perkins, J. Carl Barrett, Stephen D. Hursting, L. Michelle Bennett, and David Berrigan ........................................................................................................ 1076


A DNA Methyltransferase Inhibitor and All-trans Retinoic Acid Reduce Oral Cavity Carcinogenesis Induced by the Carcinogen 4-Nitroquinoline 1-Oxide. Xiao-Han Tang, Martin Albert, Theresa Scognamiglio, and Lorraine J. Gudas ........................................................................................................ 1090

Reviewers

Acknowledgement to Reviewers. ........................................................................................................ 1111
About the Cover

The cover photographs illustrate the dramatic suppression of muscle-invasive bladder cancer by intravesically administered rapamycin, which inhibits the mammalian target of rapamycin (mTOR), in a genetically engineered mouse model of progression from pre-invasive to invasive bladder cancer. The larger, muscle-invasive tumor (top) developed in a mouse treated with control vehicle; the smaller, non-muscle–invasive tumor (bottom) developed in a mouse treated with rapamycin. The measures numbered along the x and y axes are centimeters. These findings are the first to demonstrate the chemopreventive effectiveness of a molecular-targeted agent given intravesically in a relevant murine bladder model; they support broadening the study of intravesical therapeutic agents in high-risk non-muscle–invasive bladder cancer patients and provide a preclinical mouse model for testing novel such agents. Showing that intravesical delivery of an mTOR inhibitor blocks progression to invasive disease provides new hope for patients at a high risk for developing muscle-invasive bladder cancer, for whom few treatment options exist. See articles by Seager et al. (beginning on page 1008) and McConkey and Dinney (beginning on page 1001) for more information.